GC
CARM

Guggenheim Capital’s Carisma Therapeutics CARM Stock Holding History

Guggenheim Capital’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-517
Closed -$17K – 2891
2016
Q2 		$17K Hold
517
– – ﹤0.01% 2818
2016
Q1 		$3K Buy
+517
New +$7.15K ﹤0.01% 2901

Other funds holding CARM

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DTL
Dynamic Technology Lab Singapore $615M AUM 11.3% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Guggenheim Capital's CARM Position: Q3 2016 in Review

Guggenheim Capital sold out of Carisma Therapeutics (CARM) in Q3 2016, closing a stake of 517 shares — an estimated $17K sold.

Guggenheim Capital first reported a position in CARM in Q1 2016 and held it in 2 quarters. The position peaked at $17K in Q2 2016. 29 funds tracked by Wall St. Rank hold CARM as of Q3 2016.

  • Guggenheim Capital reported no remaining Carisma Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Guggenheim Capital sold 517 Carisma Therapeutics shares in Q3 2016, an estimated $17K.
  • Guggenheim Capital first reported a position in Carisma Therapeutics in Q1 2016 and held it in 2 quarters.
  • Guggenheim Capital's Carisma Therapeutics position peaked at $17K in Q2 2016.
  • 29 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2016.

Based on Guggenheim Capital's 13F filing for Q3 2016, filed 15 Nov 2016.